Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide plus bendamustine for graft-versus-host disease prophylaxis after haploidentical stem cell transplantation
IRCT20230801058996N13Phase 2Not yet recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and bendamustine in graft-versus-host disease (GVHD), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of treatment-related adverse events and 4 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
cyclophosphamidebendamustine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on IRCT20230801058996N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230801058996N13.